Actelion Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
57
About the Report
About the Report
Summary
Actelion Pharmaceuticals Ltd (Actelion), subsidiary of Johnson & Johnson is a biopharmaceutical company, which discovers, develops and commercializes innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary arterial hypertension (PAH). Its PAH franchise products include endothelin receptor antagonists (ERAs) Tracleer (bosentan), Opsumit (macitentan), Veletri (epoprostenol for injection), Ventavis (iloprost) and Uptravi (selexipag). Its specialty products include Valchlor (mechlorethamine), Ledaga (chlormethine) and Zavesca (miglustat). Actelion also offers approved treatments for diseases such as Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients with systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. The company offers its products in various countries across Europe, besides Japan, China, Russia, Mexico and the US. Actelion is headquartered in Allschwil, Switzerland.
Actelion Pharmaceuticals Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Actelion Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Enamine Expands Agreement with Actelion 14
SynAging Extends Agreement with Actelion Pharma 15
Handok Enters into Agreement with Actelion Pharmaceuticals 16
Actelion Forms Joint Venture with Max Planck Society 17
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 18
Licensing Agreements 19
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 19
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 20
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 21
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 22
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 24
Equity Offering 25
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 25
Asset Transactions 26
Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma 26
Acquisition 27
Johnson & Johnson Acquires Actelion for USD30 Billion 27
Actelion Plans to Acquire ZS Pharma 29
Actelion Rejects Acquisition Offer from Shire 30
Tetraphase Pharma May Sell Itself 31
Actelion Completes Acquisition Of Ceptaris Therapeutics For USD 250 Million 33
Actelion Pharmaceuticals Ltd-Key Competitors 36
Actelion Pharmaceuticals Ltd-Key Employees 37
Actelion Pharmaceuticals Ltd-Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 42
Financial Announcements 42
Feb 14, 2017: Actelion announces excellent financial results for 2016 42
Corporate Communications 46
Aug 06, 2018: Alzheon appoints former IVAX president, Neil Flanzraich, JD, as vice chairman of board of directors 46
Jun 09, 2017: Publication of Idorsia's prospectus relating to the listing of Idorsia on SIX Swiss Exchange 47
May 15, 2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson 49
Product Approvals 50
Aug 30, 2018: Actelion submits application to EMA seeking approval of OPSUMIT (macitentan) for the treatment of Chronic Thromboembolic Pulmonary Hypertension 50
Apr 30, 2018: Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) 52
Clinical Trials 53
Jan 23, 2017: Actelion announces results of the MAESTRO study with macitentan in patients with pulmonary arterial hypertension due to Eisenmenger Syndrome 53
Other Significant Developments 55
May 22, 2017: Actelion provides an update on the progress towards launching Idorsia-Key results for pipeline assets to be developed by Idorsia 55
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
List of Figure
List of Figures
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Actelion Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Actelion Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Actelion Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Enamine Expands Agreement with Actelion 14
SynAging Extends Agreement with Actelion Pharma 15
Handok Enters into Agreement with Actelion Pharmaceuticals 16
Actelion Forms Joint Venture with Max Planck Society 17
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 18
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 19
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 20
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 21
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 22
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 24
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 25
Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma 26
Johnson & Johnson Acquires Actelion for USD30 Billion 27
Actelion Plans to Acquire ZS Pharma 29
Actelion Rejects Acquisition Offer from Shire 30
Tetraphase Pharma May Sell Itself 31
Actelion Completes Acquisition Of Ceptaris Therapeutics For USD 250 Million 33
Actelion Pharmaceuticals Ltd, Key Competitors 36
Actelion Pharmaceuticals Ltd, Key Employees 37
Actelion Pharmaceuticals Ltd, Subsidiaries 38
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.